Short Interest in Immunocore Holdings plc (NASDAQ:IMCR) Declines By 5.4%

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 7,190,000 shares, a decrease of 5.4% from the November 15th total of 7,600,000 shares. Based on an average daily trading volume, of 277,800 shares, the short-interest ratio is presently 25.9 days. Approximately 14.8% of the shares of the stock are sold short.

Immunocore Price Performance

Shares of NASDAQ IMCR traded up $0.07 during mid-day trading on Tuesday, hitting $29.40. 456,981 shares of the company's stock traded hands, compared to its average volume of 498,440. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76. Immunocore has a 1 year low of $28.17 and a 1 year high of $76.98. The company's 50-day moving average is $32.25 and its two-hundred day moving average is $35.09. The company has a market capitalization of $1.47 billion, a P/E ratio of -30.69 and a beta of 0.73.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company's quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.59) earnings per share. On average, equities analysts anticipate that Immunocore will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on IMCR. UBS Group started coverage on Immunocore in a research report on Thursday, October 24th. They issued a "sell" rating and a $24.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Immunocore in a report on Monday, September 9th. Mizuho lowered shares of Immunocore from an "outperform" rating to a "neutral" rating and cut their price objective for the company from $72.00 to $38.00 in a report on Monday, November 11th. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th. Finally, Guggenheim lowered shares of Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday, October 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of "Moderate Buy" and an average target price of $65.64.

Institutional Trading of Immunocore

A number of institutional investors have recently bought and sold shares of IMCR. Envestnet Asset Management Inc. raised its stake in shares of Immunocore by 0.9% in the second quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company's stock valued at $2,392,000 after acquiring an additional 606 shares during the period. Pier Capital LLC raised its position in Immunocore by 1.4% in the 3rd quarter. Pier Capital LLC now owns 82,480 shares of the company's stock worth $2,568,000 after purchasing an additional 1,174 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in Immunocore by 6.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company's stock worth $767,000 after purchasing an additional 1,390 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in shares of Immunocore by 40.4% during the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company's stock valued at $158,000 after buying an additional 1,461 shares during the period. Finally, Assetmark Inc. grew its stake in shares of Immunocore by 6.5% during the third quarter. Assetmark Inc. now owns 30,555 shares of the company's stock valued at $951,000 after buying an additional 1,878 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.